Icure Pharmaceutical exports joint pain reliever Ketoprofen Plaster to Singapore

Icure Pharmaceutical said Tuesday that it has signed a contract with UITC to export Ketoprofen Plaster, used to treat joint pain, stiffness, and swelling in conditions like  rheumatoid arthritis, osteoarthritis, and acute musculoskeletal injuries.

UITC, a company that distributes pharmaceutical products in Hong Kong, Malaysia, and Singapore, will participate in the Singapore government tender project. The scale of product supply will depend on the size of the tender project.

Icure explained that it has recently signed contracts for the supply of plasters and cataplasmas worth about 15 billion won ($10.8 million) to Latin America, the U.K., and the UAE. The company also continues its global supply contract for donepezil patch.

According to Icure, the company has signed over 60 billion won agreements, including a distribution agreement for Southeast Asia with Menarini of Italy and a distribution agreement for the Middle East and Africa with Pharma Bavaria of Portugal.

Icure is a contract development and manufacturing organization (CDMO) that develops and produces patches and plasters based on transdermal drug delivery system (TDDS) technology and is also engaged in the cosmetics ODM/OBM business. It operates a pharmaceutical KGMP and cosmetics CGMP-certified factory in Wanju-gun, North Jeolla Province, and is preparing for overseas GMP certification.

“We will maximize our sales and profits by improving domestic sales structure and increasing capacity utilization rate through full-scale exports,” Icure CEO Lee Young-seok said.